Variables | No recurrence (n = 51) | AF recurrence (n = 25) | p value |
---|---|---|---|
Age (years) | 65 ± 9 | 66 ± 8 | 0.728 |
Gender (male) | 26 (51.0%) | 13 (52.0%) | 0.933 |
Body mass index (kg/m2) | 25.74 ± 3.46 | 26.13 ± 3.65 | 0.710 |
Smoking (%) | 21 (41.2%) | 7 (28.0%) | 0.263 |
Persistent atrial fibrillation (%) | 14 (27.5%) | 19 (76.0%) | < 0.001 |
Duration of atrial fibrillation (months) | 24 ± 5 | 60 ± 15 | 0.090 |
Comorbidity | Â | Â | Â |
 Hypertension (%) | 26 (51.0%) | 11 (44.0%) | 0.567 |
 Diabetes mellitus (%) | 13 (25.5%) | 9 (36.0%) | 0.343 |
 Coronary artery disease (%) | 5 (9.8%) | 4 (16.0%) | 0.432 |
Medications | Â | Â | Â |
 Statins | 22 (43.1%) | 12 (48.0%) | 0.689 |
 ACEI/ARB | 40 (78.4%) | 18 (72.0%) | 0.536 |
Renal function | Â | Â | Â |
 Blood urea nitrogen (mmol/L) | 5.67 ± 1.60 | 5.43 ± 1.87 | 0.630 |
 Creatinine (μmol/L) | 77.58 ± 16.81 | 79.75 ± 8.85 | 0.526 |
 Creatinine clearance (mL/min) | 83.12 ± 28.23 | 79.06 ± 22.86 | 0.616 |
Echocardiographic data | Â | Â | Â |
 Left atrial diameter (mm) | 39.0 ± 3.5 | 44.9 ± 2.1 | < 0.001 |
 Left ventricular end-diastolic diameter (mm) | 46.3 ± 3.9 | 46.9 ± 4.2 | 0.593 |
 Left ventricular end-systolic diameter (mm) | 28.0 ± 3.1 | 27.5 ± 2.1 | 0.411 |
 Left ventricular ejection fraction (%) | 69.0 ± 5.8 | 70.0 ± 3.5 | 0.354 |
NT-proBNP (pg/ml) | 204.50 ± 56.35 | 347.80 ± 35.80 | < 0.001 |
Ablation protocol (persistent AF) | n=14 | n=19 | Â |
 CAPV+additional linear ablation | 8 (57.1%) | 9 (47.4%) | 0.728 |
 CAPV+LA "roof" line | 8 (57.1%) | 9 (47.4%) | 0.728 |
 CAPV+LA "mitral isthmus" line | 8 (57.1%) | 9 (47.4%) | 0.728 |
Ablation protocol (paroxysmal AF) | n=37 | n=6 | Â |
 CAPV+additional linear ablation | 7 (18.9%) | 2 (33.3%) | 0.589 |
 CAPV+LA "roof" line | 7 (18.9%) | 2 (33.3%) | 0.589 |
 CAPV+LA "mitral isthmus" line | 5 (13.5%) | 0 | - |